|
|
|
By Tim Sandle, Ph.D. | Improving microbiology laboratory efficiency is a continuum. Here are five tech-forward trends that will impact cost and efficiency in 2025. |
|
|
|
By Peter H. Calcott, Ph.D., FRSC, Calcott Consulting LLC | FDA's CDER recently issued a draft guidance: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. This article provides a summary and analysis. The public comment period ends January 14, 2025. |
|
|
|
|
|
|
|
|
|
|
|
|
|
